Elevar Therapeutics, Inc. ("Elevar"), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group ("Tanner"), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named patient basis in areas outside of the United States (U.S.) where Apealea is not commercially available. Apealea has been approved by the European regulatory authorities for use in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

Tanner Pharma Group, Inc. announced they have partnered with Endo Pharmaceuticals, Inc. to initiate a multi-year Named Patient Program for XIAFLEX® (collagenase clostridium histolyticum), an important nonsurgical treatment option for patients with Dupuytren’s contracture and Peyronie’s disease.

Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation, a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

Tanner Pharmaceuticals, Inc., a global pharma services company that provides access to pharmaceuticals through Global Access Programmes and Clinical Trials Sourcing, and BurnsAdler Pharmaceuticals, a specialty pharmaceutical company that licenses and acquires pharmaceuticals, medical devices and over-the-counter (OTC) products for commercialization in Latin America and other international markets, have merged to form Tanner Pharma Group, company officials announced today.